Wall Street Access Asset Management buys $5,240,042 stake in Luminex Corporation (LMNX)

Luminex Corporation (LMNX) : Wall Street Access Asset Management scooped up 500 additional shares in Luminex Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 244,519 shares of Luminex Corporation which is valued at $5,240,042.Luminex Corporation makes up approximately 3.07% of Wall Street Access Asset Management’s portfolio.

Other Hedge Funds, Including , Diam Ltd. boosted its stake in LMNX in the latest quarter, The investment management firm added 18,890 additional shares and now holds a total of 116,498 shares of Luminex Corporation which is valued at $2,496,552. Luminex Corporation makes up approx 0.04% of Diam Ltd.’s portfolio.Louisiana State Employees Retirement System boosted its stake in LMNX in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 17,100 shares of Luminex Corporation which is valued at $381,330. Luminex Corporation makes up approx 0.02% of Louisiana State Employees Retirement System’s portfolio. 1st Global Advisors sold out all of its stake in LMNX during the most recent quarter. The investment firm sold 29,459 shares of LMNX which is valued $649,866.Capstone Asset Management Co boosted its stake in LMNX in the latest quarter, The investment management firm added 1,900 additional shares and now holds a total of 16,780 shares of Luminex Corporation which is valued at $369,999. Luminex Corporation makes up approx 0.01% of Capstone Asset Management Co’s portfolio.

Luminex Corporation closed down -0.13 points or -0.59% at $21.92 with 3,10,213 shares getting traded on Monday. Post opening the session at $22.2, the shares hit an intraday low of $21.76 and an intraday high of $22.21 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Luminex Corporation reported $0.33 EPS for the quarter, beating the analyst consensus estimate by $ 0.15 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.18. The company had revenue of $64.17 million for the quarter, compared to analysts expectations of $61.00 million. The company’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.

Luminex Corporation is a developer manufacturer and marketer of biological testing technologies with applications throughout the clinical diagnostic and life science industries. The Company’s xMAP (Multi-Analyte Profiling) technology is being used within fields of drug discovery and development and for clinical diagnostics genetic analysis bio-defense food safety and biomedical research. In addition to its xMAP technology the Company has its MultiCode technology used for real-time polymerase chain reaction (PCR) and multiplexed PCR assays. The instruments in the Company’s xMAP line include LX200 system which offers 100-plex testing; FLEXMAP 3D system which is a 500-plex testing system; and MAGPIX system which provides 50-plex testing at a lower cost using imaging rather than flow cytometry. The Company’s products include Instruments Consumables Software and Assay Product Families.

Leave a Reply

Luminex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Luminex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.